Karolina Juszczyk1, Sharlyn Kang2,3, Soni Putnis1, Robert Winn1, James Chen2, Morteza Aghmesheh3,4, Glaucia Fylyk5, Daniel Brungs3,4. 1. Division of Surgery, Colorectal Unit, Wollongong Hospital, NSW, Australia. 2. Department of Radiation Oncology, Illawarra Cancer Care Centre, Wollongong Hospital, NSW, Australia. 3. Illawarra Health and Medical Research Institute, University of Wollongong, NSW, Australia. 4. Department of Medical Oncology, Illawarra Cancer Care Centre, Wollongong Hospital, NSW, Australia. 5. Department of Radiation Oncology, Shoalhaven Cancer Care Centre, Shoalhaven Hospital, NSW, Australia.
Abstract
BACKGROUND: The impact of increased body mass index (BMI) on clinical outcomes in locoregional rectal cancer is unknown. METHODS: This is a retrospective cohort study which included 453 consecutive rectal cancer patients undergoing definitive treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of BMI at diagnosis with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) was explored, controlling for key covariates using multivariable analyses. BMI as defined by the World Health Organization (WHO) is as follows: BMI <18.5-underweight; 18.5-24.9-normal; 25.0-29.9-pre-obesity; >30-obese. RESULTS: Overweight and obese patients had significantly better OS than underweight/normal weight patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight patients, P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62 (0.4-0.8) P=0.007] and multivariable [0.65 (0.4-0.9) P=0.023] analyses. When stratified by stage, high BMI was associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I (0.54). High BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048) and multivariable analyses (HR 0.58, P=0.03). CONCLUSIONS: In our study a BMI greater than 25 is significantly associated with a longer OS and CSS in patients with locoregional rectal cancer. These findings may be due to the reduced metabolic capacity for non-obese patients to deal with rectal cancer treatment as well as the burden of disease, however further research is needed to evaluate this. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
BACKGROUND: The impact of increased body mass index (BMI) on clinical outcomes in locoregional rectal cancer is unknown. METHODS: This is a retrospective cohort study which included 453 consecutive rectal cancer patients undergoing definitive treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of BMI at diagnosis with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) was explored, controlling for key covariates using multivariable analyses. BMI as defined by the World Health Organization (WHO) is as follows: BMI <18.5-underweight; 18.5-24.9-normal; 25.0-29.9-pre-obesity; >30-obese. RESULTS: Overweight and obese patients had significantly better OS than underweight/normal weight patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight patients, P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62 (0.4-0.8) P=0.007] and multivariable [0.65 (0.4-0.9) P=0.023] analyses. When stratified by stage, high BMI was associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I (0.54). High BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048) and multivariable analyses (HR 0.58, P=0.03). CONCLUSIONS: In our study a BMI greater than 25 is significantly associated with a longer OS and CSS in patients with locoregional rectal cancer. These findings may be due to the reduced metabolic capacity for non-obese patients to deal with rectal cancer treatment as well as the burden of disease, however further research is needed to evaluate this. 2020 Journal of Gastrointestinal Oncology. All rights reserved.
Entities:
Keywords:
Body mass index (BMI); cancer; obesity; rectal cancer; survival
Authors: Gertraud Maskarinec; Brook E Harmon; Melissa A Little; Nicholas J Ollberding; Laurence N Kolonel; Brian E Henderson; Loic Le Marchand; Lynne R Wilkens Journal: Cancer Causes Control Date: 2015-09-10 Impact factor: 2.506
Authors: Peter T Campbell; Christina C Newton; Polly A Newcomb; Amanda I Phipps; Dennis J Ahnen; John A Baron; Daniel D Buchanan; Graham Casey; Sean P Cleary; Michelle Cotterchio; Alton B Farris; Jane C Figueiredo; Steven Gallinger; Roger C Green; Robert W Haile; John L Hopper; Mark A Jenkins; Loïc Le Marchand; Karen W Makar; John R McLaughlin; John D Potter; Andrew G Renehan; Frank A Sinicrope; Stephen N Thibodeau; Cornelia M Ulrich; Aung Ko Win; Noralane M Lindor; Paul J Limburg Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-02 Impact factor: 4.254